Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Oxygen, Imperial College London Collaborate on Organ Failure Trial

August 6, 2014 10:56 am | News | Comments

Oxygen Biotherapeutics Inc. announced a collaboration with Imperial College London to provide supplemental funding to support the accelerated enrollment and completion of the ongoing LeoPARDS Trial awarded by the Efficacy and Mechanism Evaluation Programme and funded by the Medical Research Council and managed by the National Institute for Health Research. Read more...

TOPICS:

Psoriasis, RA Drug Shows Good Efficacy

August 6, 2014 10:45 am | News | Comments

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced new data from a retrospective analysis of its autoimmune disease advanced trials that shows high efficacy of its orally bioavailable drug CF101. Read more...

TOPICS:

Ventana Paves the Way for Companion Diagnostics in China

August 6, 2014 10:39 am | News | Comments

Ventana Medical Systems Inc., a member of the Roche Group, announced a new agreement with Quintiles Inc. to offer College of American Pathology-standard companion diagnostic testing services in China for pharmaceutical and biotech companies conducting early phase clinical trials. Read more...

TOPICS:
Advertisement

Cancer Cells Look for a Soft Bed

August 6, 2014 10:31 am | News | Comments

Cancer cells that break away from tumors to go looking for a new home may prefer to settle into a soft bed, according to new findings from researchers at the University of Illinois published in the journal Nature Communications. Read more...

TOPICS:

EU Approves Avastin for Ovarian Cancer

August 6, 2014 10:24 am | News | Comments

Roche announced that the European Commission approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy. Read more...

TOPICS:

Obama Seeks Executive Steps to Curb Tax Inversions

August 6, 2014 10:18 am | by Josh Lederman, Associated Press | News | Comments

Aiming to sidestep a logjam in Congress, the Obama administration is looking for steps it could take on its own to prevent American companies from reincorporating overseas to shirk U.S. taxes, officials said Tuesday in an election-year push that Democrats hope will appeal to middle-class voters. Read more...

TOPICS:

C. Difficile Prophylactic Program Remains on Track

August 5, 2014 3:01 pm | News | Comments

Synthetic Biologics Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced that, with a new multi-service agreement in place, the company is on track to initiate Phase 1a and 1b clinical trials of SYN-004 for the prevention of Clostridium difficile. Read more...

TOPICS:

Nanoscale Thin-Film Technique Promises Long-Term Drug Delivery

August 5, 2014 2:50 pm | by Peter Dizikes, MIT News Office | News | Comments

About one in four older adults suffers from chronic pain. Many of those people take medication, usually as pills. But this is not an ideal way of treating pain: Patients must take medicine frequently, and can suffer side effects, since the contents of pills spread through the bloodstream to the whole body. Read more...

TOPICS:
Advertisement

IPF Drug Receives Orphan Drug Designation

August 5, 2014 2:38 pm | News | Comments

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, announced the U.S. Food and Drug Administration has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program - inhaled GP-101 for the treatment of idiopathic pulmonary fibrosis (IPF). Read more...

TOPICS:

Paclitaxel Reformulated for Bolus Intraperitoneal Injection

August 5, 2014 2:30 pm | News | Comments

A repurposed drug originally used to treat ovarian cancer saw positive results for patients with advanced peritoneal cancers during a phase 1 clinical trial at The University of Kansas Cancer Center, during which it was administered as a bolus injection directly into the peritoneum through a catheter. Read more...

TOPICS:

Paradigm Kicks Off Genomic Profiling for Cancer Registry

August 5, 2014 2:16 pm | News | Comments

Paradigm has announced they have initiated genomic testing for Pharmatech's AccessPPM Cancer Registry, which is designed to collect EMR data and genomic information to help best match cancer patients with targeted clinical trials. Read more... 

TOPICS:

Scientists Use Subcellular Imaging to Visualize Glutamate Receptors

August 5, 2014 2:08 pm | News | Comments

Scientists at the National Institutes of Health have created high-resolution images of the glutamate receptor, a protein that plays a key role in nerve signaling. The advance, published online in the journal Nature, opens a new window to study protein interactions in cell membranes in exquisite detail. Read more...

TOPICS:

Novimmune to Start Proof of Concept Study for RA Drug

August 5, 2014 11:02 am | News | Comments

Novimmune SA announced the completion of a comprehensive Phase 1 clinical trial investigating the pharmacokinetics, pharmacodynamics, preliminary tolerability and safety of NI-0101, a first-in-class monoclonal antibody against toll-like receptor 4, in presence and absence in vivo of a TLR4 ligand. Read more...

TOPICS:

Parkinson's Drug Eligible for EU Centralized Procedure

August 5, 2014 10:57 am | News | Comments

NeuroDerm Ltd. announced that the European Medicines Agency has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa treatment for advanced Parkinson's disease, eligible for a European Union marketing authorization application procedure ("centralized procedure"). Read more...

TOPICS:

Glioblastoma Triple Therapy Revs Up Immune System

August 5, 2014 10:52 am | News | Comments

A triple therapy for glioblastoma, including two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report by scientists at the Johns Hopkins Kimmel Cancer Center. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading